BRIEF—Elevar inks commercialization deal for TKI candidate

Abu Dhabi-based drug manufacturer Neopharma has formed a joint venture in UAE with USA-based Elevar Therapeutics.

The firms plan to establish a sales network for rivoceranib, also known as apatinib, a tyrosine kinase inhibitor candidate  under development in gastric cancer.

Should the therapy be approved, Neopharma will undertake commercialization in various countries of the MENA region and in India.